Saturday - May 10, 2025
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to present at the iAccess Alpha Best Ideas Spring Virtual Conference taking place March 12th and 13th.
iAccess Alpha Best Ideas Spring Virtual Conference
Presentation Date: March 12, 2024
Presentation Time: 10:30 a.m. ET
Live Webcast Registration: https://www.webcaster4.com/Webcast/Page/3024/50043
To schedule a 1x1 meeting, please contact your iAccess Alpha conference representative or KCSA by emailing NEXGEL@kcsa.com.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com
Last Trade: | US$2.59 |
Daily Change: | -0.02 -0.58 |
Daily Volume: | 27,363 |
Market Cap: | US$17.590M |
November 13, 2024 November 11, 2024 October 10, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load